MedPath

Research of second line anti-diabetes drug for patients with Type-2 diabetes who received Sitagliptin as first line.

Not Applicable
Conditions
Type II diabetes mellitus
Registration Number
JPRN-UMIN000014467
Lead Sponsor
Fukuoka Tokushukai Medical Center Psychosomatic Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
132
Inclusion Criteria

Not provided

Exclusion Criteria

Moderate to severe renal dysfunction Dialysis patient Medical history of heart failure,bowel obstruction

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change and rate of change in HbA1c , 24 weeks later.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath